Skip to content
In Stock Actos
Diabetes

Actos

Actos helps the body respond more effectively to its own insulin, lowering elevated blood glucose in adults with type 2 diabetes. Its active ingredient, pioglitazone, is taken as an oral tablet and…

Guaranteed quality Original product
Delivery: from 4 days Discreet shipping
24/7 Support Always available
Active ingredient: Pioglitazone
Select dosage:
Select pack Package Per unit Price
$ 2.61 $ 156.64
$ 2.27 $ 234.96 $ 204.70 Save 13%
$ 2.12 $ 313.28 $ 254.54 Save 19%
$ 1.96 $ 469.92 $ 352.44 Save 25%
Free Regular Delivery $ 1.88 $ 626.56 $ 452.12 Save 28%
Best value Free Express Delivery $ 1.81 $ 939.84 $ 651.48 Save 31%
$ 2.94 $ 176.22
$ 2.61 $ 264.33 $ 234.96 Save 11%
$ 2.43 $ 352.44 $ 291.92 Save 17%
Free Regular Delivery $ 2.23 $ 528.66 $ 400.50 Save 24%
Free Express Delivery $ 2.12 $ 792.99 $ 573.16 Save 28%
Best value Free Express Delivery $ 2.04 $ 1,057.32 $ 735.14 Save 30%
$ 3.62 $ 108.58
$ 2.88 $ 217.16 $ 172.66 Save 20%
$ 2.57 $ 325.74 $ 231.40 Save 29%
$ 2.34 $ 434.32 $ 281.24 Save 35%
Best value Free Regular Delivery $ 2.09 $ 651.48 $ 375.58 Save 42%

Free delivery on orders from $ 356.00, free express delivery from $ 534.00

Secure payment methods:
VISA AMEX JCB DISCOVER

Actos helps the body respond more effectively to its own insulin, lowering elevated blood glucose in adults with type 2 diabetes. Its active ingredient, pioglitazone, is taken as an oral tablet and may be used alone or with other glucose-lowering treatments when clinically appropriate.

Product information

Its active ingredient, pioglitazone, is taken as an oral tablet and may be used alone or with other glucose-lowering treatments when clinically appropriate.

Ingredients

Actos contains pioglitazone, an oral thiazolidinedione used for glycaemic management in adults with type 2 diabetes mellitus. Pioglitazone improves insulin sensitivity in tissues such as skeletal muscle, adipose tissue and the liver, allowing insulin to regulate glucose more effectively [1].

Actos tablets are taken by mouth. The treatment is intended for type 2 diabetes, not for type 1 diabetes or diabetic ketoacidosis. It does not replace dietary planning, physical activity or regular glucose monitoring.

The dose is decided individually, taking age, other medicines and health conditions into account. Clinicians also consider kidney and liver status, heart function, fracture risk and the person’s existing diabetes regimen before prescribing pioglitazone.

Actos may be prescribed:

  • As monotherapy when other treatment is unsuitable or insufficient.
  • With metformin when additional insulin sensitivity is needed.
  • With a sulfonylurea when blood glucose remains above the agreed target.
  • With insulin in selected patients who require combination treatment.
  • As part of a longer-term plan that includes monitoring of glycated haemoglobin and symptoms.

Pioglitazone works gradually. It does not provide the rapid glucose-lowering effect associated with short-acting insulin.

Weight increase after starting pioglitazone can reflect fluid retention as well as changes in body fat. A rapid increase over several days, especially with ankle swelling or breathlessness, needs prompt medical assessment.

Therapeutic indications

The treatment is intended for type 2 diabetes, not for type 1 diabetes or diabetic ketoacidosis.

Actos may be prescribed:

  • As monotherapy when other treatment is unsuitable or insufficient.
  • With metformin when additional insulin sensitivity is needed.
  • With a sulfonylurea when blood glucose remains above the agreed target.
  • With insulin in selected patients who require combination treatment.
  • As part of a longer-term plan that includes monitoring of glycated haemoglobin and symptoms.

Directions for use

  • Dose: The dose of Actos is decided individually, taking age, other medicines and health conditions into account.
  • Frequency: Take the prescribed oral tablet according to the regimen provided by the treating clinician.
  • Timing: Take Actos as directed in the prescribed treatment regimen.
  • Duration: Use Actos as part of a longer-term treatment plan that includes monitoring of glycated haemoglobin and symptoms.
  • Route: Take the tablet by mouth.

When not to use it

Actos is not suitable for everyone. This medication is not for you if you have symptomatic heart failure, active liver disease, diabetic ketoacidosis, or a previous serious reaction to pioglitazone.

Specific situations requiring medical assessment include:

  • A history of heart failure or significant fluid overload.
  • Abnormal liver tests or chronic liver disease.
  • Osteoporosis or previous fragility fracture.
  • Unexplained blood in the urine.
  • Bladder cancer or a history of bladder cancer.
  • Pregnancy, planned pregnancy or breastfeeding.
  • Use of insulin, a sulfonylurea or medicines affecting pioglitazone metabolism.
  • Significant vision changes or diabetic macular oedema.
  • Anaemia or unexplained fatigue.

Pioglitazone is not intended for type 1 diabetes or diabetic ketoacidosis.

The medicine may interact with gemfibrozil, rifampicin and ketoconazole.

When this is not for you

Actos is generally avoided in symptomatic heart failure because fluid retention can aggravate the condition. People with osteoporosis, a history of low-trauma fractures, liver problems, unexplained blood in the urine or significant vision changes should discuss treatment with a clinician before taking it.

Women who have not yet reached menopause may ovulate more regularly after insulin sensitivity improves. This can lead to unexpected pregnancy in someone who previously had irregular cycles. Contraceptive planning may need review.

Unwanted effects

The main tolerability concerns with Actos are weight gain, oedema and hypoglycaemia when combined with insulin or sulfonylureas. Other reported effects include headache, upper respiratory symptoms, muscle pain and visual changes associated with diabetic eye disease.

Fluid retention can appear as tight shoes, sock marks, swollen ankles or a change in how far a person can walk without becoming breathless. Some people notice weight gain before they feel unwell. Weighing at a consistent time can make a rapid change easier to identify.

Serious problems requiring medical attention include:

  • New or worsening breathlessness.
  • Rapid swelling of the legs or abdomen.
  • Chest discomfort or fainting.
  • Yellowing of the skin or eyes.
  • Dark urine with unusual fatigue.
  • Blood in the urine or painful urination.
  • Sudden visual changes.
  • A fracture after a minor fall.

Pioglitazone has been associated with bone fractures, with risk reported more often in women in some clinical data. People with osteoporosis or a history of low-trauma fractures need an individual assessment.

Rare liver injury is possible. Symptoms such as persistent nausea, upper abdominal discomfort, loss of appetite, dark urine or jaundice should not be ignored.

Do not treat progressive ankle swelling as ordinary weight gain. The distinction matters because fluid retention can worsen heart failure even when blood glucose readings look better.

Mechanism of action

Pioglitazone activates the nuclear receptor PPAR-γ, influencing the transcription of genes involved in glucose transport and insulin responsiveness. This increases insulin sensitivity in tissues that handle glucose, helping the body respond more effectively to its own insulin and lowering elevated blood glucose.

Common mistakes

Several practical errors can reduce the benefit of Actos or delay recognition of a problem:

  • Expecting a noticeable glucose change after the first tablet.
  • Stopping treatment when readings improve without an agreed plan.
  • Ignoring ankle swelling because the glucose result is satisfactory.
  • Taking extra tablets after one high reading.
  • Forgetting to mention pioglitazone before starting gemfibrozil, rifampicin or ketoconazole.
  • Assuming that metformin or a sulfonylurea has the same fluid-retention profile.
  • Missing regular diabetes reviews while continuing combination treatment.
  • Treating sudden breathlessness as a minor side effect.
  • Failing to report blood in the urine or new urinary symptoms.
  • Continuing a sulfonylurea or insulin dose unchanged after repeated low readings.

The dose should not be changed independently. Pioglitazone’s effect develops gradually, so a short-term high reading does not show that an additional tablet is needed.

If a dose is missed, do not double the next dose. Resume the prescribed schedule unless the treating clinician has provided different instructions for your regimen.

Comparison

Pioglitazone occupies a different pharmacological role from medicines that increase insulin secretion or reduce intestinal glucose absorption.

Treatment category Main action Practical distinction
Pioglitazone Improves insulin sensitivity through PPAR-γ activation Gradual effect; oedema, weight gain and fracture risk require attention
Metformin Reduces hepatic glucose production and improves insulin sensitivity Often used as a foundation treatment; gastrointestinal symptoms can occur
Sulfonylurea Stimulates pancreatic insulin release Can lower glucose promptly but carries a greater hypoglycaemia risk

Metformin is often selected early because it does not usually cause weight gain or fluid retention. Pioglitazone may be considered when insulin resistance remains prominent or when another mechanism is needed.

Sulfonylureas act on pancreatic beta cells and can reduce glucose more quickly. Their limitation is a greater risk of hypoglycaemia, especially when meals are delayed or food intake is reduced. Pioglitazone does not directly stimulate insulin release, so its low-glucose risk is lower when used alone.

Insulin remains essential for type 1 diabetes and may be required in advanced type 2 diabetes. Adding pioglitazone to insulin can increase fluid retention, so this combination demands careful selection and follow-up.

What doctors say

In clinical practice, physicians usually judge pioglitazone by the trend in glycated haemoglobin, fasting glucose and symptoms of fluid retention rather than by a single home glucose result.

A doctor may describe the main benefit as improved insulin sensitivity, with the main trade-off being a slower onset and the possibility of weight gain or oedema. The treatment can be useful for selected people with marked insulin resistance, but it is a poor fit for someone with symptomatic heart failure.

Liver function is assessed when clinically appropriate, especially if symptoms suggest liver injury. Doctors also review the full diabetes regimen because hypoglycaemia may come from insulin or a sulfonylurea added to pioglitazone.

The WHO describes type 2 diabetes as a chronic condition requiring sustained glucose management and cardiovascular risk reduction. NICE guidance also supports treatment planning based on glucose targets and relevant comorbidities. Pioglitazone addresses one part of that plan; it does not treat blood pressure, cholesterol, kidney disease or cardiovascular risk on its own [2].

What customers often ask

Is Actos suitable for older adults?

Older adults may use pioglitazone when the expected benefit outweighs the risks, but prescribing requires attention to heart function, fractures, liver status and concurrent medicines. The TGA’s safety information supports individual assessment rather than an age-only rule, and its guidance remains clinically relevant in 2026. Older people may also be more vulnerable to complications from oedema and low blood glucose when Actos is combined with insulin or a sulfonylurea. A slower treatment review is often appropriate when several medicines are involved. Follow-up should reflect heart function, fracture risk and the full diabetes regimen.

How soon does the effect of Actos become noticeable?

Pioglitazone works progressively because it changes insulin-responsive gene activity through PPAR-γ. Clinical improvement may begin over several weeks, while the full glucose-lowering effect can take longer to assess. EMA product information from 2018 describes the need to evaluate treatment response over time rather than after one or two doses. A high reading early in treatment does not justify taking an extra tablet.

Can Actos be taken with food or on an empty stomach?

Actos tablets may generally be taken with or without food, provided the daily schedule remains consistent. The EMA product information from 2018 describes oral administration without requiring a meal-specific timing rule. Taking the tablet at the same time each day can make missed doses less likely. Food does not remove the need to monitor for oedema, low glucose with combination treatment or other adverse effects.

How does Actos differ from the closest alternative?

Actos contains pioglitazone, which activates PPAR-γ and improves insulin sensitivity. Metformin works through a different mechanism, with a major effect on hepatic glucose production, while sulfonylureas stimulate pancreatic insulin release. WHO guidance from 2023 recognises that type 2 diabetes often requires treatment tailored to comorbidities, adverse-effect risks and glucose targets. Pioglitazone may be useful when insulin resistance is a central issue, but fluid retention and weight gain can make another mechanism preferable.

How long does one Actos dose keep working?

Pioglitazone has a prolonged pharmacological effect, so it is administered as a regular daily treatment rather than repeated several times during the day. Its active metabolites also contribute to the sustained effect. The FDA prescribing information from 2016 describes the extended activity of pioglitazone and its metabolites, which helps explain why a missed dose should not be replaced with a double dose. The clinical effect is measured across repeated doses and glucose trends, not by a single tablet.

Can people drive or operate machinery while taking Actos?

Actos alone does not usually impair concentration or coordination. Driving ability can be affected if hypoglycaemia occurs, especially when pioglitazone is combined with insulin or a sulfonylurea. The TGA information from 2024 identifies low blood glucose as a treatment-related concern in combination regimens, so drivers should know their symptoms and follow their diabetes plan. Blurred vision, dizziness, confusion or weakness should be treated as a reason to stop operating machinery until the cause is addressed.

Do you offer anonymous delivery?

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.

Comparison

Actos Current

Active ingredient: Pioglitazone
15mg 30mg 45mg
From $ 108.58
pills
4 (3)

Amaryl

Active ingredient: Glimepiride
2mg 3mg 4mg 1mg
From $ 149.52
pills
4.1 (5)

Empagliflozin

Active ingredient: Empagliflozin
10mg 25mg
From $ 332.86
pills
4.1 (5)

Forxiga

Active ingredient: Dapagliflozin
10mg 5mg
From $ 229.62
pills
4.3 (4)

Glucophage

Active ingredient: Metformin
1000mg 500mg 850mg 250mg
From $ 181.56
pills
3.9 (5)

Karela

Active ingredient: Karela
250mg
From $ 218.94
pills
3.5 (5)

How the medicines for Diabetes compare

Sources

  1. European Medicines Agency (2011). Summary of Product Characteristics (SmPC) — Actos (pioglitazone)
  2. World Health Organization (2023). Diabetes fact sheet

How Buyers Rate Actos

Based on 3 reviews

Oliver K., 61 Verified
Rating: 4 out of 5

I used pioglitazone at my prescribed daily dose alongside my existing diabetes treatment for several months. My readings became steadier, but ankle swelling appeared during the second month, so my doctor reviewed the combination and my weight.

Several months 25 Oct 2026
David, 34 Verified
Rating: 4.5 out of 5

After taking my prescribed daily dose for about six weeks, my morning readings were lower and less erratic. I did not notice much during the first fortnight, which made me wonder whether it was doing anything.

About six weeks 31 Oct 2026
Michael, 46 Verified
Rating: 3.5 out of 5

The medicine helped my glucose control after several weeks at my prescribed daily dose, but I gained weight and felt uncomfortable after meals. The benefit was real, although the fluid-retention warning became more relevant to me than I expected.

Several weeks 5 Oct 2026
Get our free app Shop faster and track your orders 3.8 · 491 reviews Install